HUNTSVILLE, Ala., Oct. 2, 2024 /PRNewswire/ -- Ambetter of Alabama, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer a variety of affordable health insurance plans to Alabamans in 39 counties for plan year 2025. Open enrollment for the Health Insurance Marketplace for Alabama runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15 for coverage starting Jan. 1, 2025.
Ambetter of Alabama offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Below is a full list of counties in which Ambetter of Alabama will be offered in 2025:
Alabama residents interested in learning more about Ambetter of Alabama or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/al.
About Ambetter of Alabama
Ambetter of Alabama serves under-insured and uninsured populations through the federal Health Insurance Marketplace®. Ambetter of Alabama is underwritten by Celtic Insurance Company, which is a Qualified Health Plan issuer in Alabama. For more information, visit ambetterhealth.com/en/al. This is a solicitation for insurance. For information on your right to receive an Ambetter of Alabama plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$59.91 |
Daily Change: | -0.15 -0.25 |
Daily Volume: | 2,154,699 |
Market Cap: | US$30.250B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB